MET gene alterations linked to worse outcomes in solid tumors

Patients with advanced solid tumors with MET gene amplification and fusion had a worse response to chemotherapy and significantly shorter overall survival (OS) and progression-free survival (PFS) than patients without amplification or fusion, according to a study.

Of the 2239 patients with cancer, most having colorectal (n = 702), gastric (n = 481), and sarcoma (n = 180), who underwent next-generation sequencing, 2.1% demonstrated MET gene amplification and 0.4% demonstrated MET gene fusion. All MET-amplified tumors had microsatellite stable status, with 8 demonstrating a high tumor mutational burden.

Patients with amplification of MET gene fusion were found to have a shorter OS and PFS and the authors concluded that MET aberration was a factor to chemotherapy response.

Reference
Ko J, Jung J, Kim ST, et al. MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer. Pathol Oncol Res. 2022;28:1610697. doi: 10.3389/pore.2022.1610697. PMID: 36483096; PMCID: PMC9722768.